<< Back

Arnaud Fontanet



Spring 2015:
  • Global Outbreak Alert and Response
Spring 2016:
  • Global Outbreak Alert and Response
Spring 2017:
  • Global Outbreak Alert and Response
PSIA Programs: Concentration in Global Health, Concentration in Global Risks



I am a medical epidemiologist (MD in 1988 at Paris V, specialisation in rheumatology in 1990, Paris V, and DrPH from Harvard School of Public Health in 1993) specialized in infectious diseases epidemiology.  After working at WHO at the clinical research unit of the Global Program on AIDS (1993-1994), I spent five years in Ethiopia and two years in the Netherlands working as the Program Manager of the Ethio-Netherlands AIDS Research Project (1994-2001). In 2002, I joined Institut Pasteur to launch the Emerging Diseases Epidemiology unit.  There, my focus has been on viral hepatitis C (North-Coordinator of the ANRS research site on viral hepatitis; www.hepnile.org) and emerging infections such as the SARS (Scientific Coordinator of the EPISARS project which aimed prevent the re-emergence of SARS through the control of its animal reservoir - SP22-CT-2004-511063) and the MERS-CoV.  I also have a strong teaching involvement, as co-Director and founder of the Pasteur-Cnam School of Public Health (http://ecole-pasteur.cnam.fr), and coordinator of a master in public health with strong focus on infectious diseases. In 2014, I was appointed as Director of the newly created Pasteur Centre for Global Health Research and Education.


 I have now more than 150 publications in international peer-reviewed journals available at:



The diseases I have published on are by decreasing order of frequencies:

-         AIDS: 55

-         Hepatitis C: 39

-         Emerging viral diseases (SARS, MERS-CoV, …): 17

-         Malaria: 16

-         Buruli ulcer: 10

-         Fungi diseases: 9

-         Tuberculosis: 6

-         Others: 9


Below are four recent papers, three on hepatitis C (my main research activity), and one on MERS-Coronavirus (as an example of my work on emerging viruses).

 ·     Laird ME, Mohsen A, Duffy D, Mamdouh R, LeFouler L, Casrouge A, El-Daly M, Rafik M, Abdel-Hamid M, Soulier A, Pawlotsky JM, Hézode C, Rosa I, Renard P, Mohamed MK, Bonnard P, Izopet J, Mallet V, Pol S, Albert ML, Fontanet A. Apolipoprotein H expression is associated with IL28B genotype and viral clearance in Hepatitis C virus infection, J Hepatol (IF 2014: 10.4). 2014;61:770-6.

 ·     Breban R, Arafa N, Leroy S, Mostafa A, Bakr I, Tondeur L, Abdel-Hamid M, Doss W, Esmat G, Mohamed MK, Fontanet A. Modelling the impact of preventive and curative interventions on HCV transmission in a high prevalence setting: The case of Egypt. The Lancet Glob Health (IF not known yet). 2014;2:e541-9.

 ·     Thursz M, Fontanet A. HCV transmission in industrialized countries and resource-constrained areas.  Nature Reviews Gastroenterol Hepatol (IF 2014: 10.8). 2014;11:28-35.

 ·       Breban R, Riou J, Fontanet A. Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk.  Lancet (IF 2014: 39.2). 2013;382:694-9.




Member for
5 years 49 weeks